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1. Introduction
Data on present problem 
published in the last years in 
scientific literature testify inter-
linking of metabolic syndrome 
to typical gastroenterological 
manifestations – steatosis of the 
liver and pancreas, cholelithiasis, 
cholesterosis of the gallbladder 
[1, 2]. The basic role in develop-
ment of metabolic disorders with 
insulin resistance syndrome is 
supposed, on one hand, to ste-
atosis of the liver and, on the 
other hand, to hyperinsulinemia, 
hyperglycemia and dyslipidemia, 
that aggravate gastroenterolog-
ical problems [3, 4]. In the au-
thor’s opinion, inf lammation, 
intimately conjugated to devel-
opment of steatohepatitis, con-
comitant diseases and their com-
plications (mainly obesity, which 
is obligatory for metabolic syn-
drome) is the trigger of comorbid 
digestive pathology progression 
at metabolic syndrome [5, 6]. 
A healthy liver can readily 
handle a lifetime’s worth of di-
etary fat, but a failing liver cannot. 
The liver can be overtaxed by 
excess dietary fat. Triglycerides 
can build up in hepatocytes if 
the liver’s mitochondrial beta-ox-
idation and very–low-density li-
poprotein production are insuffi-
cient to handle the fatty acid load. 
Over time, this fat accumulation 
can lead to scarring, inflamma-
tion, fibrosis, and cirrhosis—the 
progressive stages of nonalcoholic 
fatty liver disease (NAFLD) [7].
Currently, nonalcoholic fatty 
liver disease is one of the most 
common chronic liver diseases in 
the world [8]. NAFLD is classified 
into two types: hepatic steatosis 
and nonalcoholic steatohepatitis 
(NASH). Hepatic steatosis is a re-
versible condition in which large 
vacuoles of triglyceride fat accu-
mulate in the liver cells, causing 
nonspecific inflammation. Most 
people with this condition experi-
ence few, if any, symptoms, and it 
does not usually lead to scarring or 
serious liver damage. The majority 
of patients with NAFLD have this 
type. NASH is the more severe, 
progressive form that involves not 
only fat accumulation (steatosis) in the liver but also inflamma-
tion. Steatohepatitis can lead to fibrosis and eventually to cirrho-
sis, which is severe scarring that can lead to liver failure [9, 10]. 
NAFLD occurs in most peo-
ple with obesity, the main path 
of progression is the process of 
fibrogenesis [11, 12], which is ac-
companied by the deposition of 
components of the extracellu-
lar matrix (collagen of different 
types, fibronectin, etc.) in peris-
inusoidal spaces, which leads to 
structural and functional failure 
of the organ. 
The real frequency of the 
prevalence of the disease is dif-
ficult to establish, due to the 
insufficient use of non-invasive 
screening diagnostic methods, 
through which it is possible to 
detect the initial forms of the 
disease [13]. Studies confirm the 
possibility of diagnosing fibrosis 
in non-alcoholic fatty liver dis-
ease using non-invasive meth-
ods [14, 15], but their use in 
pediatric practice is not known 
until now. Therefore, the search 
for biochemical markers of liver 
fibrosis, which are highly sen-
sitive, informative and can be 
used in children, is very relevant 
today.
The aim of our research. 
To improve the effectiveness of 
noninvasive diagnosis of liver fi-
brosis in adolescents with obesity 
using serum biomarkers of liver 
fibrogenesis.
2. Methods
On the base of SI “Insti-
tute of children and adolescents 
health care of the NAMS” we- 
re inspected 226 patients with 
obesity in age 8–18 years and 
30 healthy children for control 
group. 
Investigation of liver fi-
brogenesis consisted of mea-
surement in blood serum of fi-
bronectin level («Biochimmak» 
(Russia), 70±14.0 mkg/ml), se- 
rum collagen type IV («Argutus 
Medical» (Japan), 99±2,3 mkg/l), 
N-terminal propeptides of type 
I collagen (N-TP) («Biomedica» 
(Austria)). C-terminal telopep-
tides of type I collagen (C-TT) 
(«Immunodiagnostic Systems 
Ltd» (UK)) is index of fibrolysis. 
Statistical processing was made 
by program Statistics+. 
Тhe normal content of propeptides and telopeptides accord-
ing to the referential values of the test kit tested on the control 
group, are presented in the Table 1.
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Abstract: Non-alcoholic fatty liver disease occurs in most 
obese people, the main pathway of which is the process of fi-
brogenesis. This disorder is currently classified into two types: 
hepatic steatosis and nonalcoholic steatohepatitis. Hepatic 
steatosis is a reversible condition in which large vacuoles of 
triglyceride fat accumulate in the liver cells, causing nonspecif-
ic inflammation. Most people with this condition experience 
few, if any, symptoms, and it does not usually lead to scarring 
or serious liver damage. The majority of patients with nonal-
coholic fatty liver disease have this type. Nonalcoholic steato-
hepatitis is the more severe, progressive form that involves not 
only fat accumulation (steatosis) in the liver but also inflam-
mation. Steatohepatitis can lead to fibrosis and eventually to 
cirrhosis, which is severe scarring that can lead to liver failure.
The real frequency of the prevalence of the disease is diffi-
cult to establish, due to the insufficient use of non-invasive 
screening diagnostic methods, through which it is possible to 
detect the initial forms of the disease. 
The aim: to study the diagnostic significance of the serum 
biomarkers of liver fibrogenesis in adolescents with obesity. 
Methods. On the base of the Department of Endocrinolo-
gy, SI “Institute of children and adolescence health care of 
NAMS” (Kharkov) 226 patients with obesity aged 8–18 years 
were examined. Investigation of liver fibrosis consisted of 
measurement in blood the levels of fibronectin, collagen type 
IV, N-terminal propeptides and C-terminal telopeptides of 
type I collagen by IFA method.
Results. The study of liver fibrogenesis revealed a significant 
increase in levels of type IV collagen and fibronectin in chil-
dren with obesity (p<0.05). As diagnostic criteria for two phys-
iologically diverse processes – fibrogenesis and fibrolysis, the 
levels of N-terminal propeptides and C-terminal telopeptides 
of type I collagen, respectively, were determined. The serum 
level of N-terminal propeptides of type I collagen significantly 
exceeds the normal values in all children with obesity, in con-
trast to the children of the control group (p<0.05).
Conclusion. It has been established that a biochemical meth-
od for determining the level of type IV collagen, fibronectin, 
N-terminal propeptides and C-terminal telopeptides of type 
I collagen has a high sensitivity for the diagnosis of liver fi-
brogenesis.
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It was found that 113 (50.0±3.33 %) patients had insulin 
resistance (IR). The study of liver fibrogenesis revealed a signif-
icant increase in levels of type IV collagen and fibronectin in 
children with obesity (p<0.05), (Table 2). The levels of fibronec-
tin blood significantly differed in groups, depending on the 
presence of IR, which apparently indicates a more severe liver 
damage in children with IR (p<0.05).
Table 2
Levels of collagen type IV and fibronectin in adolescents with 
obesity, depending on the presence of IR (M±σ)
Children with 
obesity n
Collagen type ІV, 
mkg/l Fibronectin, mkg/ml
ІR + 113 107.61±7.04* 115.86±7.20*, **
ІR – 113 103.76±8.31* 93.00±6.31* 
Control group 30 85.91±2.38 78.36±2.12
Note: * – Difference between patients with obesity and healthy children 
(p<0.05); ** – Difference between patients with IR and without it (p<0.05) 
As diagnostic criteria for two physiologically diverse pro-
cesses - fibrogenesis and fibrolysis, the levels of N-TP and C-TT 
of type I collagen, respectively, were determined. The serum 
level of N-TP of type I collagen significantly exceeds the normal 
values in all children with obesity, in contrast to the children of 
the control group (p<0.05) (Table 3).
In patients with IR, the level of N-TP of type I collagen 
were more elevated than in the group without IR, which indi-
cates a more intensive process of liver fibrogenesis 
in the presence of insulin resistance.
The levels of C-TT of type I collagen in children 
with obesity were within the norms and did not 
differ statistically significantly from those in the 
control group (p>0.05) (Table 4).
Exceptions are children of early pubertal age, 
in whom the indicators of the marker of fibrolysis 
were significantly lower than in children of the 
control group (p<0.05). Apparently, this is due to 
the predominance of fibrogenesis processes over 
fibrolysis, which is typical for liver fibrosis.
4. Discussion
The obtained results do not contradict the existing ones 
and confirm the expediency of using non-invasive methods 
of diagnosing non-alcoholic fatty liver disease in pediatric 
practice. The advantage of using these methods is to improve 
the early diagnosis of non-alcoholic fatty liver disease in 
children, the observation and prevention of progression and 
complications. Although liver biopsy is the most accurate mo-
dality to diagnose and stage the severity of NASH, this method 
suffers from being invasive, costly, associated with potential 
complications, and plagued with interobserver variability of 
individual pathological features. Of the various serum mark-
ers, fibronectin, collagen type IV, N-terminal propeptides 
and C-terminal telopeptides of type I collagen seems to best 
predict fatty liver disease, the NAFLD Fibrosis Score is most 
closely correlated with fibrosis, and transient elastography 
can be used for diagnosis of cirrhosis, or to exclude cirrhosis, 
although its utility is limited by obesity [16].
Thus, non-invasive diagnostic methods using serum bio-
markers of hepatic fibrosis (type IV collagen, fibronectin, 
N-terminal propeptides and C-terminal telopeptides of type I 
collagen) have confirmed their diagnostic sensitivity in estab-
lishing the presence of liver fibrogenesis processes on the early 
stages formation in children with obesity. In the future, this will 
increase the efficiency of early diagnosis of fatty liver disease, 
dynamic observation of a patient with control of biochemical 
parameters of liver fibrosis and improve treatment and preven-
tion measures.
Table 1
The content of normal level N-terminal propeptides and C-terminal 
telopeptides of type I collagen in serum in children of different age groups
N-terminal propeptides of type I collagen, pmol/l
Prepubertal period Pubertal period Postpubertal period
boys girls boys girls boys girls
4.52±0.324 5.87±0.334 6.1±0.274 4.98±0.268 4.9±0.352 3.75±0.147
C-terminal telopeptides of type I collagen, ng/ml
1.883±0.374 2.029±0.361 2.281±0.474 2.266±0.368 1.069±0.552 0.821±0.447
Table 3
The levels of N-terminal propeptides of type I collagen in children with obesity (M±σ)
Children with obesity
N-terminal propeptides of type I collagen, pmol/l
Prepubertal period (n=32) Pubertal period (n=92) Postpubertal period (n=102)
boys girls boys girls boys girls
ІR + (n=113) 9.03±0.21*, ** 11.12±1.60*, ** 8.6±1.04* 7.42±0.76* 8.28±0.80*, ** 5.51±0.88*, **
ІR – (n=113) 6.98±0.65* 5.9±0.77* 9.536±1.84* 6.903±0.61* 7.806±0.94* 4.536±0.52*
Control group (n=30) 4.45±0.13 5.64±0.14 6.21±0.16 4.81±0.12 5.08±0.13 3.79±0.11
Note: * – Difference between patients with obesity and healthy children (p<0.05); ** – Difference between patients with IR and without it (p<0.05)
Table 4
The levels of C-terminal telopeptides of type I collagen in children with obesity (M±σ)
Children with obesity
C-terminal telopeptides of type I collagen, ng/ml
Prepubertal period (n=32) Pubertal period (n=92) Postpubertal period (n=102)
boys girls boys girls boys girls
ІR + (n=113) 1.86±0.41 1.921±0.14 1.88±0.18* 1.673±0.18* 1.291±0.08 1.134±0.14
ІR – (n=113) 1.72±0.25 1.927±0.42 1.888±0.34* 1.281±0.10* 1.218±0.13 0.733±0.06
Control group (n=30) 1.52±0.32 1.89±0.43 2.61±0.71 2.47±0.68 1.23±0.25 0.89±0.19
Note: * – Difference between patients with obesity and healthy children (p<0.05)
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